多发性骨髓瘤的B细胞成熟抗原靶向嵌合抗原受体T细胞治疗与复发后处理的研究进展  

Advances in BCMA⁃CAR⁃T therapy of multiple myeloma and management after relapse

作　　者：燕思佳 肖毅[1] YAN Sijia;XIAO Yi(Department of Hematology,Tongji Hospital,Tongji Medical College of Huazhong University of Science and Tech-nology,Wuhan 430030,Hubei,China)

机构地区：[1]华中科技大学同济医学院附属同济医院血液内科,湖北武汉430030

出　　处：《实用医学杂志》2025年第7期929-935,共7页The Journal of Practical Medicine

基　　金：国家自然科学基金项目(编号:81873444,82070213,82370196)。

摘　　要：多发性骨髓瘤(MM)是一种较常见的血液系统恶性肿瘤,虽然有多种药物可用于其治疗,但仍不可避免复发。近年来B细胞成熟抗原(BCMA)靶向嵌合抗原受体T(CAR-T)细胞治疗在治疗复发/难治性(R/R)MM方面取得了极大的成就,为RRMM患者带来了新的希望。目前国内外已有4种BCMA-CAR-T产品上市,其在RRMM中的应用越来越广泛。但是,BCMA-CAR-T治疗后的RRMM仍有较高的复发率,而对于BCMA-CAR-T后的维持治疗方面的研究仍较少,BCMA-CAR-T治疗复发后的治疗有多种选择。Multiple myeloma(MM)is a prevalent hematological malignancy.Despite the availability of various therapeutic agents,disease relapse remains inevitable.In recent years,B cell maturation antigen(BCMA)⁃targeted chimeric antigen receptor T(CAR⁃T)cell therapy has demonstrated remarkable success in treating relapsed/refractory(R/R)MM,offering new hope for RRMM patients.Currently,four types of BCMA⁃CAR⁃T products are available on the global market,and their application in RRMM is becoming increasingly widespread.However,RRMM patients who receive BCMA⁃CAR⁃T treatment still exhibit a high relapse rate.Research on maintenance therapy following BCMA⁃CAR⁃T treatment is currently limited,and multiple strategies exist for managing postrelapse RRMM after BCMA⁃CAR⁃T therapy.

关 键 词：多发性骨髓瘤 B细胞成熟抗原靶向嵌合抗原受体T细胞治疗 复发 

分 类 号：R552[医药卫生—血液循环系统疾病]